OSLO, Norway, Sept. 19, 2019 /PRNewswire/ -- One former
employee and a participant in the Company's previous share option
program, not being a primary insider, has exercised a total number
of 5,775 options through exercise of a corresponding number of
free-standing warrants. The options are exercised at a strike price
of NOK 14.24. Each free-standing
warrant gives the right to receive one share in the Company.
The share capital increase related to the exercise of the
options has been duly registered in the Norwegian Register of
Business Enterprises. Following the registration, the Company's
share capital is NOK 11,023,894.20
divided into 55,119,471 shares, each with a nominal value of
NOK 0.20.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's
current expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--increased-share-capital-following-exercise-of-employee-share-options,c2909309
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-increased-share-capital-following-exercise-of-employee-share-options-300921766.html
SOURCE Nordic Nanovector